Post-earnings recap
Reported
Fri, Nov 9, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a narrower loss than expected, which contributed to a positive stock reaction, with shares rising by 5.93%. However, there was no revenue reported or guidance provided, leaving some uncertainty about future performance. Investors may view the EPS beat as a sign of improving operational efficiency.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | +25.53% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.